Polyfactorial approach in the correction of cognitive impairment in patients with post-Covid syndrome

The article discusses a multi-level polyfactorial approach in the correction of cognitive impairment in patients with post-Covid syndrome based on the combined use of cognitive-motivational correction of the psychological state and physiotherapeutic methods of  treatment: multi-level magnetolaser therapy, advanced blood irradiation, transcranial neuroacoustic and light-pulse stimulation. According to the results of the analysis of the results of testing patients based on the Montreal scale for assessing cognitive functions before the start, after 6 and 12 procedures, as well as 4 weeks after the completion of rehabilitation in the first group, the average indicators of the level of cognitive functions changed from 18.2 to 21.4 points, in the second group from 17 to 26 points. Psychological testing using the psychometric tables of A. Beck and Spielberger-Hanin showed a decrease in the average level of depression after the procedures in the first group by 5.4±1.4 (from 27.5 to 22.1) points, the anxiety level by 4.9±0.3 (from 35.1 to 30.2), in the second group by 9.9±1.2 (from 27.3 to 17.4) and 8.2±0.4 (from 35.2 to 27.0), respectively. Additionally, it should be noted that the clients of the second group were more interested in conducting a second course. A multi-level approach in the medical rehabilitation of patients with post-Covid syndrome based on the use of psychological correction, magnetolaser effect on the projection of the liver, supravenous irradiation of blood and combined transcranial neuroacoustic and light-pulse stimulation in combination with endonasal breathing of a singlet-oxygen mixture in a magnetic field turned out to be the most effective for restoring cognitive functions

Stable autosolitons in dispersive media with saturable gain and absorption

We introduce the simplest one-dimensional model of a dispersive optical medium with saturable dissipative nonlinearity and filtering (dispersive loss) which gives rise to stable solitary pulses (autosolitons). In the particular case when the dispersive loss is absent, the same model may also be interpreted as describing a stationary field in a planar optical waveguide with uniformly distributed saturable gain and absorption. In a certain region of the model's parameter space, two coexisting solitary-pulse solutions are found numerically, one of which may be stable. Solving the corresponding linearized eigenvalue problem, we identify stability borders for the solitary pulses in their parametric plane. Beyond one of the borders, the symmetric pulse is destroyed by asymmetric perturbations, and at the other border it undergoes a Hopf bifurcation, which may turn it into a breather.Comment: A latex text file and four ps files with figures. Physics Letters A, in pres

Smart Data Placement for Big Data Pipelines: An Approach based on the Storage-as-a-Service Model

The development of big data pipelines is a challenging task, especially when data storage is considered as part of the data pipelines. Local storage is expensive, hard to maintain, comes with several challenges (e.g., data availability, data security, and backup). The use of cloud storage, i.e., Storageas-a-Service (StaaS), instead of local storage has the potential of providing more flexibility in terms of such as scalability, fault tolerance, and availability. In this paper, we propose a generic approach to integrate StaaS with data pipelines, i.e., computation on an on-premise server or on a specific cloud, but integration with StaaS, and develop a ranking method for available storage options based on five key parameters: cost, proximity, network performance, the impact of server-side encryption, and user weights. The evaluation carried out demonstrates the effectiveness of the proposed approach in terms of data transfer performance and the feasibility of dynamic selection of a storage option based on four primary user scenarios.acceptedVersio

2-year single center clinical experience in patients with colon cancer stage II and III receiving adjuvant chemotherapy

Introduction: Colorectal cancer is the most commonly diagnosed gastrointestinal cancer worldwide. For patients without metastatic disease, surgery is the first option used with curative intention, for stage I disease the adequate treatment consists only of surgical excision. In stage III additional adjuvant chemotherapy post-surgery is recommended. In stage II colon cancer, adjuvant treatment remains controversial.We aim to stratify patients according to different criteria, identify those with recurrence within the first year post last cycle of adjuvant chemotherapy and discuss those primary results.Materials and methods: a total of 52 patients who were subject to curative resection of stage II and III colon adenocarcinoma and who were administrated 5 FU based adjuvant chemotherapy were included and were followed for a period of two years. Data analysis was performed.Result: After a mean of 2 years of follow-up, recurrence was identified in 16 patients. None of stage II patients (n=6) and 3 patients in stage III (n=6) experienced recurrence. Patients with Nx cancer (n=30) were detached in separate group. Thirteen of them experienced recurrence (9 patients had relapse within 6 months after surgery - defined as synchronous metastatic disease).Conclusion: Surgery remains the cornerstone of treatment for the majority of colon patients. The selection of optimal chemotherapy for each patient is a complex process and there is a practice evidence gap which remains a significant problem. Our results for relapse are comparable with the reported ones worldwide. The reports suggest that there is still lack of evidence in the adjuvant colon cancer chemotherapy worldwide

Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019

Background: The sustainable development goals (SDGs) aim to end HIV/AIDS as a public health threat by 2030. Understanding the current state of the HIV epidemic and its change over time is essential to this effort. This study assesses the current sex-specific HIV burden in 204 countries and territories and measures progress in the control of the epidemic. Methods: To estimate age-specific and sex-specific trends in 48 of 204 countries, we extended the Estimation and Projection Package Age-Sex Model to also implement the spectrum paediatric model. We used this model in cases where age and sex specific HIV-seroprevalence surveys and antenatal care-clinic sentinel surveillance data were available. For the remaining 156 of 204 locations, we developed a cohort-incidence bias adjustment to derive incidence as a function of cause-of-death data from vital registration systems. The incidence was input to a custom Spectrum model. To assess progress, we measured the percentage change in incident cases and deaths between 2010 and 2019 (threshold >75% decline), the ratio of incident cases to number of people living with HIV (incidence-to-prevalence ratio threshold <0·03), and the ratio of incident cases to deaths (incidence-to-mortality ratio threshold <1·0). Findings: In 2019, there were 36·8 million (95% uncertainty interval [UI] 35·1–38·9) people living with HIV worldwide. There were 0·84 males (95% UI 0·78–0·91) per female living with HIV in 2019, 0·99 male infections (0·91–1·10) for every female infection, and 1·02 male deaths (0·95–1·10) per female death. Global progress in incident cases and deaths between 2010 and 2019 was driven by sub-Saharan Africa (with a 28·52% decrease in incident cases, 95% UI 19·58–35·43, and a 39·66% decrease in deaths, 36·49–42·36). Elsewhere, the incidence remained stable or increased, whereas deaths generally decreased. In 2019, the global incidence-to-prevalence ratio was 0·05 (95% UI 0·05–0·06) and the global incidence-to-mortality ratio was 1·94 (1·76–2·12). No regions met suggested thresholds for progress. Interpretation: Sub-Saharan Africa had both the highest HIV burden and the greatest progress between 1990 and 2019. The number of incident cases and deaths in males and females approached parity in 2019, although there remained more females with HIV than males with HIV. Globally, the HIV epidemic is far from the UNAIDS benchmarks on progress metrics. Funding: The Bill & Melinda Gates Foundation, the National Institute of Mental Health of the US National Institutes of Health (NIH), and the National Institute on Aging of the NIH

The global burden of cancer attributable to risk factors, 2010-19 : a systematic analysis for the Global Burden of Disease Study 2019

Background Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. Findings Globally, in 2019, the risk factors included in this analysis accounted for 4.45 million (95% uncertainty interval 4.01-4.94) deaths and 105 million (95.0-116) DALYs for both sexes combined, representing 44.4% (41.3-48.4) of all cancer deaths and 42.0% (39.1-45.6) of all DALYs. There were 2.88 million (2.60-3.18) risk-attributable cancer deaths in males (50.6% [47.8-54.1] of all male cancer deaths) and 1.58 million (1.36-1.84) risk-attributable cancer deaths in females (36.3% [32.5-41.3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20.4% (12.6-28.4) and DALYs by 16.8% (8.8-25.0), with the greatest percentage increase in metabolic risks (34.7% [27.9-42.8] and 33.3% [25.8-42.0]). Interpretation The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.Peer reviewe

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation

Magnetic order in the two-dimensional compass-Heisenberg model

A Green-function theory for the dynamic spin susceptibility in the square-lattice spin-1/2 antiferromagnetic compass-Heisenberg model employing a generalized mean-field approximation is presented. The theory describes magnetic long-range order (LRO) and short-range order (SRO) at arbitrary temperatures. The magnetization, Néel temperature TN, specific heat, and uniform static spin susceptibility χ are calculated self-consistently. As the main result, we obtain LRO at finite temperatures in two dimensions, where the dependence of TN on the compass-model interaction is studied. We find that TN is close to the experimental value for Ba2IrO4. The effects of SRO are discussed in relation to the temperature dependence of χ

Magnetic susceptibility and short-range order in iron pnictides: Anisotropic J

A spin-rotation-invariant Green-function theory for the dynamic spin susceptibility in the anisotropic non-frustrated J1-J2 model for the iron pnictides AFe2As2 (A = Ca, Sr, Ba) is presented. The two-spin correlation functions, the spin-excitation spectrum, and the staggered magnetization are calculated self-consistently as functions of temperature and spin. The temperature dependence of the magnetic (uniform static) susceptibility, in particular the linear increase with T in a wide temperature region that is in good quantitative agreement with experiments, is ascribed to a strong in-plane antiferromagnetic short-range order. The values of the Néel temperature resulting from the localized spin model with realistic out-of-plane couplings are found to be much higher than the measured values. From this an extension of the model by including itinerant degrees of freedom is suggested

Spin excitations and thermodynamics of the antiferromagnetic Heisenberg model on the layered honeycomb lattice

We present a spin-rotation-invariant Green-function theory for the dynamic spin susceptibility in the spin-1/2 antiferromagnetic Heisenberg model on a stacked honeycomb lattice. Employing a generalized mean-field approximation for arbitrary temperatures, the thermodynamic quantities (two-spin correlation functions, internal energy, magnetic susceptibility, staggered magnetization, Néel temperature, correlation length) and the spin-excitation spectrum are calculated by solving a coupled system of self-consistency equations for the correlation functions. The temperature dependence of the magnetic (uniform static) susceptibility is ascribed to antiferromagnetic short-range order. The Néel temperature is calculated for arbitrary interlayer couplings. Our results are in a good agreement with numerical computations for finite clusters and with available experimental data on the β-Cu2V2O2 compound